Age of onset of myocardial infarction: Is promoter polymorphism of the RAGE gene implicated?

Rejuvenation Research

Volumn 14, Issue 1, 2011, Pages 67-73

  Boiocchi, Chiara ^a,b   Bozzini, Sara ^a   Buzzi, Maria Paola ^a   Schirinzi, Sandra ^a   Zorzetto, Michele ^c   Pelissero, Gabriele ^d   Cuccia, Mariaclara ^b   Falcone, Colomba ^b  

^a Research in Molecular Medicine (CIRMC)   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR;

AGE OF ONSET; ANTIGENS, NEOPLASM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 79951825591     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2010.1091     Document Type: Article

References (32)

1. Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, Herrington DM, Hong Y, Jaquish C, McDermott DA, O'Donnell CJ. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: A scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-2901. (Pubitemid 46869676)
2. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009;27:165-197.
3. Novelli G, Borgiani P, Giardina E, Mango R, Contino G, Romeo F, Mehta JL. Role of genetics in prevention of coronary atherosclerosis. Curr Opin Cardiol 2003;18:368-371. (Pubitemid 37153689)
4. Scheuner MT. Genetic predisposition to coronary artery disease. Curr Opin Cardiol 2001;16:251-260. (Pubitemid 32751892)
5. Incalcaterra E, Hoffmann E, Averna MR, Caimi G. Genetic risk factors in myocardial infarction at young age. Minerva Cardioangiol. 2004;52:287-212.
6. Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci 2009;14:1403-1413.
7. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21.
8. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93: 1159-169. (Pubitemid 37543056)
9. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008;14:979-986. (Pubitemid 351753286)
10. Jandeleit-Dahm K, Watson A, Soro-Paavonen A. The AGE/ RAGE axis in diabetes-accelerated atherosclerosis. Clin Exp Pharmacol Physiol 2008;35:329-334. (Pubitemid 351260012)
11. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006;185:70-77. (Pubitemid 43117552)
12. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-2469.
13. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-955. (Pubitemid 32946067)
14. Gao ZQ, Yang C, Wang YY, Wang P, Chen HL, Zhang XD, Liu R, Li WL, Qin XJ, Liang X, Hai CX. RAGE upregulation and nuclear factor-kappaB activation associated with ageing rat cardiomyocyte dysfunction. Gen Physiol Biophys 2008;27:152-158.
15. Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, Lu X, Chen BH, Shan YX, Tian JW, Nagaraj RH, Xie D, Zhang X. Advanced oxidation protein products activate vascular en-dothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008;10:1699-1712.
16. Takahashi HK, Mori S, Wake H, iu K, Yoshino T, Ohashi K, Tanaka N, Shikata K, Makino H, Nishibori M. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 2009;330:89-98.
17. Haslbeck KM, Bierhaus A, Erwin S, Kirchner A, Nawroth P, Schlotzer U, Neundorfer B, Heuss D. Receptor for advanced glycation end product (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy. Muscle Nerve 2004;29:853-860. (Pubitemid 38720822)
18. Sugaya K, Fukagawa T, Matsumoto K, Mita K, Takahashi E, Ando A, Inoko H, Ikemura T. Three genes in the human MHC class III region near the junction with the class II: Gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994;23:408-419. (Pubitemid 24308262)
19. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: Prevalence in type 2 diabetes and ethnic groups. Diabetes 1998;47:1155-1157. (Pubitemid 28294561)
20. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001;50:1505-1511. (Pubitemid 32500186)
21. Zee RY, Romero JR, Gould JL, Ricupero DA, Ridker PM. Polymorphisms in the advanced glycosylation end product-specific receptor gene and risk of incident myocardial infarction or ischemic stroke. Stroke 2006;37:1686-1690. (Pubitemid 44297713)
22. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, Groop PH; Finn-Diane Study Group. 6.The functional - 374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003;52:891-894. (Pubitemid 36323601)
23. Picheth G, Costantini CO, Pedrosa FO, Leme da Rocha Martinez T, Maltempi de Souza E. The - 374A allele of the receptor for advanced glycation end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients. Clin Chem Lab Med 2007;45:1268-1272. (Pubitemid 47557065)
24. Falcone C, Campo I, Emanuele E, Buzzi MP, Geroldi D, Belvito C, Zorzetto M, Sbarsi I, Cuccia M. - 374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin Chim Acta 2005;354:111-116. (Pubitemid 40320680)
25. Falcone C, Geroldi D, Buzzi MP, Emanuele E, Yilmaz Y, Fontana JM, Vignali L,Boiocchi C, Sbarsi I, Cuccia M. The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch Med Res 2008;39:320-325.
26. Falcone C, Emanuele E, Buzzi MP, Ballerini L, Repetto A, Canosi U, Mazzucchelli I, Schirinzi S, Sbarsi I, Boiocchi C, Cuccia M. The - 374T/A variant of the rage gene promoter is associated with clinical restenosis after coronary stent placement. Int J Immunopathol Pharmacol 2007;20:771-777.
27. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined- A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000;21:1502-1513.
28. J Am Coll Cardiol 2000;36:959-969.
29. Poon PY, Szeto CC, Chow KM, Li PK. Relation between polymorphisms of receptor for advanced glycation end products (RAGE) and cardiovascular diseases in Chinese patients with diabetic nephropathy. Clin Nephrol 2010;73:44-50.
30. Peng WH, Lu L, Wang LJ, Yan XX, Chen QJ, Zhang Q, Zhang RY, Shen WF. RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. Arch Med Res 2009;40: 393-398.
31. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-497. (Pubitemid 29138585)
32. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann NY Acad Sci 2008;1126:7-13. (Pubitemid 351589318)